Rationale:Thyroid eye disease (TED) is the most common orbital disorder in adults and significantly affects patient health. Orbital decompression surgery is an important treatment option. Central retinal artery occlusion (CRAO) after orbital medial wall decompression is rare in patients with TED. Therefore, the earlier the identification and treatment, the more likely it is to reduce visual impairment.Patient concerns:This paper examines a case of CRAO occurring postoperatively in a patient who underwent medial wall orbital decompression for TED.Diagnoses:Central retinal artery occlusion.Interventions:During the operation, the pupil was dilated, and eye massage and peribulbal injection of atropine were performed immediately. Fundus fluorescein angiography suggested the possibility of CRAO. Intravenous methylprednisolone 1000 mg, mannitol 50 g, ginkgo biloba extract 20 mL, nimodipine 20 mg tid, cobamamide 0.5 mg tid, and oral citicoline 0.2 g tid, along with periocular injection of atropine and hyperbaric oxygen therapy were also administered.Outcomes:Fifteen days after onset, the patient’s retinal edema and retinal blood perfusion greatly improved. The patient’s visual acuity recovered from counting fingers to 0.6.Lessons:Retinal vascular obstruction is a serious threat to vision; therefore, early detection and treatment are very important.

29 Oct 2024·Metal Ions in Biological Systems

Adenosylcobalamin (Vitamin B12 Coenzyme)-Dependent Enzymes

Author: Ochiai, Ei-Ichiro

A review with 37 references on catalytic mechanisms of the title enzymes.

01 Sep 2024·Synthetic and Systems Biotechnology

A hybrid RNA-protein biosensor for high-throughput screening of adenosylcobalamin biosynthesis

Article

Author: Dong, Huina ; Wang, Huiying ; Zhang, Dawei ; Ding, Dongqin ; Yang, Xia ; Fang, Huan

Genetically encoded circuits have been successfully utilized to assess and characterize target variants with desirable traits from large mutant libraries. Adenosylcobalamin is an essential coenzyme that is required in many intracellular physiological reactions and is widely used in the pharmaceutical and food industries. High-throughput screening techniques capable of detecting adenosylcobalamin productivity and selecting superior adenosylcobalamin biosynthesis strains are critical for the creation of an effective microbial cell factory for the production of adenosylcobalamin at an industrial level. In this study, we developed an RNA-protein hybrid biosensor whose input part was an endogenous RNA riboswitch to specifically respond to adenosylcobalamin, the inverter part was an orthogonal transcriptional repressor to obtain signal inversion, and the output part was a fluorescent protein to be easily detected. The hybrid biosensor could specifically and positively correlate adenosylcobalamin concentrations to green fluorescent protein expression levels in vivo. This study also improved the operating concentration and dynamic range of the hybrid biosensor by systematic optimization. An individual cell harboring the hybrid biosensor presented over 20-fold higher fluorescence intensity than the negative control. Then, using such a biosensor combined with fluorescence-activated cell sorting, we established a high-throughput screening platform for screening adenosylcobalamin overproducers. This study demonstrates that this platform has significant potential to quickly isolate high-productive strains to meet industrial demand and that the framework is acceptable for various metabolites.

100 Deals associated with Cobamamide

External Link

KEGG	Wiki	ATC	Drug Bank
D00042	Cobamamide	B03BA04	DB11191

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nutrition Disorders	China	North China Pharmaceutical Hebei Huamin Co., Ltd.	01 Jan 1995
Anemia, Megaloblastic	Japan	Eisai Co., Ltd.	19 Jan 1967
Anemia, Pernicious	Japan	Eisai Co., Ltd.	19 Jan 1967
Arthralgia	Japan	Eisai Co., Ltd.	19 Jan 1967
Central Nervous System Diseases	Japan	Eisai Co., Ltd.	19 Jan 1967
Facial Paralysis	Japan	Eisai Co., Ltd.	19 Jan 1967
Leukopenia	Japan	Eisai Co., Ltd.	19 Jan 1967
Malabsorption Syndromes	Japan	Eisai Co., Ltd.	19 Jan 1967
Myalgia	Japan	Eisai Co., Ltd.	19 Jan 1967
Neuralgia	Japan	Eisai Co., Ltd.	19 Jan 1967
Neuritis	Japan	Eisai Co., Ltd.	19 Jan 1967
Taeniasis	Japan	Eisai Co., Ltd.	19 Jan 1967
Vitamin B 12 Deficiency	Japan	Eisai Co., Ltd.	19 Jan 1967
Anemia	-	-	-
Sciatica	-	-	-
Trigeminal Neuralgia	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCD2023	Not Applicable	Leishmaniasis, Cutaneous	28	Liposomal amphotericin B 12 mg/kg	eneyxmpimi(tittjdyjzp) = bteiinlyri gldasgfktn (jkbskbglfk ) View more	Positive	06 Jul 2023
				Liposomal amphotericin B 18 mg/kg	eneyxmpimi(tittjdyjzp) = phzcisdxbg gldasgfktn (jkbskbglfk ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Cobamamide

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation